HomeCompareLIOPY vs ARCC

LIOPY vs ARCC: Dividend Comparison 2026

LIOPY yields 1.43% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LIOPY wins by $15.7K in total portfolio value· pulled ahead in Year 5
10 years
LIOPY
LIOPY
● Live price
1.43%
Share price
$16.40
Annual div
$0.23
5Y div CAGR
38.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.2K
Annual income
$6,267.32
Full LIOPY calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — LIOPY vs ARCC

📍 LIOPY pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLIOPYARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LIOPY + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LIOPY pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LIOPY
Annual income on $10K today (after 15% tax)
$121.42/yr
After 10yr DRIP, annual income (after tax)
$5,327.22/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, LIOPY beats the other by $5,326.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LIOPY + ARCC for your $10,000?

LIOPY: 50%ARCC: 50%
100% ARCC50/50100% LIOPY
Portfolio after 10yr
$32.4K
Annual income
$3,134.24/yr
Blended yield
9.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

LIOPY
No analyst data
Altman Z
3.1
Piotroski
8/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LIOPY buys
0
ARCC buys
0
No recent congressional trades found for LIOPY or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLIOPYARCC
Forward yield1.43%10.82%
Annual dividend / share$0.23$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR38.2%-50%
Portfolio after 10y$40.2K$24.5K
Annual income after 10y$6,267.32$1.16
Total dividends collected$17.9K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: LIOPY vs ARCC ($10,000, DRIP)

YearLIOPY PortfolioLIOPY Income/yrARCC PortfolioARCC Income/yrGap
1$10,897$197.41$11,381$541.15$484.00ARCC
2$11,938$277.85$12,621$284.08$683.00ARCC
3$13,167$393.14$13,827$145.31$660.00ARCC
4$14,649$560.04$15,062$73.43$413.00ARCC
5← crossover$16,479$804.74$16,364$36.89+$115.00LIOPY
6$18,802$1,169.25$17,757$18.49+$1.0KLIOPY
7$21,841$1,723.06$19,258$9.25+$2.6KLIOPY
8$25,955$2,585.22$20,880$4.63+$5.1KLIOPY
9$31,740$3,968.01$22,636$2.32+$9.1KLIOPY
10$40,229$6,267.32$24,539$1.16+$15.7KLIOPY

LIOPY vs ARCC: Complete Analysis 2026

LIOPYStock

Lion Corporation manufactures and sells consumer and industrial products in Japan and internationally. It operates through three segments: Consumer Products Business, Industrial Products Business, and Overseas Business. The company offers dental and oral care products, including toothpastes, toothbrushes, dental floss, dental rinses, mouthwashes and breath fresheners, periodontitis ointments, and denture products; body care products, such as shampoos and conditioners, hand soaps, sanitizers, wet wipes, body washes, skin and acne care products, antiperspirants and deodorants, hair-nourishment treatments, men's care and toiletries products, and foot care products. It also provides antipyretic analgesics, eye drops and eye care products, cold medicines, gargles, cold relief products, topical anti-inflammatory analgesics, antidiarrheal and gastrointestinal medicines, health tonic drinks and vitamin supplements, acne and anti-drowsiness medicines, and dermatologic agents. In addition, the company offers fabric care products, such as laundry detergent, delicate detergent, prewash treatment, stain remover, bleach, and fabric softener; clothing care products; household cleaners; kitchen cleanup products comprises dishwashing detergents and antibacterial and deodorizing products; and food preparation products. Further, it provides health and beauty food products consisting of supplements and health tonic drinks; specialty chemicals, and chemical products, include rubber processing and additive agents, mandrel release agents, fatty acid methyl esters, plant-based electrical insulating oils, concrete admixtures, ground improvement and asphalt recycling agents, surfactants, and cosmetics ingredients, as well as electro-conductive carbon black and pressure-sensitive adhesives; pet supplies; and gift and special order products. The company was founded in 1891 and is headquartered in Tokyo, Japan.

Full LIOPY Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this LIOPY vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LIOPY vs SCHDLIOPY vs JEPILIOPY vs OLIOPY vs KOLIOPY vs MAINLIOPY vs HTGCLIOPY vs GBDCLIOPY vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.